Hybrigenics and SIMM in screening and discovery collaboration
French pathway-based drug discovery company Hybrigenics has entered into a collaboration agreement with the Shanghai Institute of Materia Medica (SIMM), the Chinese Academy of Science.
French pathway-based drug discovery company Hybrigenics has entered into a collaboration agreement with the Shanghai Institute of Materia Medica (SIMM), the Chinese Academy of Science.
The agreement offers a unique opportunity to identify novel therapeutics by tapping into the area of traditional Chinese medicine using a combination of SIMM's knowledge base of several thousands plant extracts and Hybrigenics' expertise in screening and target validation.
Under the terms of the cost-sharing agreement, Hybrigenics will supply targets and a screening assay, while SIMM will provide access to its library of plant extracts based in the Chinese National Center for Drug Screening. The partners will collaborate on sample screening, hit finding, lead identification and optimisation, as well as related preclinical studies.
'Hybrigenics' know-how and discovery capabilities should enable us to further explore our natural product library with an aim of developing new drugs in oncology,' said Professor Jian Ding, deputy director of SIMM.